What is the recommended management for a patient with compensated (Child‑Pugh A) cirrhosis?

Management of Compensated (Child-Pugh A) Cirrhosis

Patients with compensated Child-Pugh A cirrhosis should be treated for their underlying etiology when possible, undergo surveillance for clinically significant portal hypertension (CSPH) and hepatocellular carcinoma (HCC), and receive non-selective beta-blockers (NSBBs) or carvedilol if CSPH is present to prevent both variceal bleeding and non-bleeding decompensation events. 1, 2

Core Management Principles

1. Treat the Underlying Cause

The most critical intervention is suppressing the etiological factor causing liver injury, as this is clearly effective in preventing decompensation and improving outcomes in compensated cirrhosis 1.

For specific etiologies:

• Hepatitis C: All treatment-naïve and treatment-experienced patients with compensated cirrhosis must be treated with direct-acting antivirals (DAAs). Use pangenotypic regimens like sofosbuvir/velpatasvir for 12 weeks 3. Treatment dramatically reduces liver complications and improves survival.
• Hepatitis B: Antiviral agents improve outcomes and should be initiated 1
• Alcohol-related cirrhosis: Complete abstinence is essential. Patients with Child-Pugh C who stop drinking have approximately 75% 3-year survival, while those who continue drinking all die within 3 years 4, 5. This dramatic difference makes alcohol cessation the single most important intervention in alcoholic cirrhosis.
• Autoimmune hepatitis: Immunosuppressive therapy should be continued 1

2. Screen for Clinically Significant Portal Hypertension (CSPH)

Use liver stiffness measurement (LSM) by transient elastography (VCTE) to stratify risk 6:

• LSM <12 kPa: CSPH excluded → Discharge from CSPH surveillance
• LSM <20 kPa: Low risk for high-risk varices → No screening endoscopy needed
• LSM 20-25 kPa: CSPH probable → Perform endoscopy if not on NSBBs/carvedilol; start treatment if varices present
• LSM >25 kPa: CSPH highly likely → Start carvedilol/NSBBs without endoscopy due to high likelihood of CSPH, or perform endoscopy if the decision to start treatment depends on varix presence

Critical concept: The goal has shifted from screening for varices to screening for CSPH. All patients with CSPH (including those with small varices) should receive beta-blockers to prevent both variceal bleeding AND non-bleeding decompensation events like ascites 6.

3. Initiate Beta-Blocker Therapy When Indicated

Beta-blockers (propranolol or carvedilol) are effective in patients with CSPH (HVPG >10 mmHg) because they reduce portal pressure in the setting of hyperdynamic circulation 6, 1. They prevent:

• Variceal hemorrhage
• Ascites development
• Other portal hypertension complications (hepatorenal syndrome, spontaneous bacterial peritonitis, hepatic encephalopathy)

Important caveat: Beta-blockers only work when CSPH is present. If CSPH resolves after successful treatment (e.g., HCV cure with sustained virologic response), discontinuation can be considered 6.

4. HCC Surveillance

All patients with compensated cirrhosis require HCC surveillance regardless of treatment response 2. Perform:

• Ultrasound every 6 months
• Consider AFP measurement, though ultrasound is the primary modality

This applies even to patients who achieve sustained virologic response after HCV treatment, as HCC risk persists though it is reduced 7.

5. Address Comorbidities and Cofactors

Target modifiable factors that accelerate cirrhosis progression 8:

• Metabolic factors: Obesity (BMI >25), diabetes, dyslipidemia
• Continued hepatotoxic exposures: Alcohol, hepatotoxic medications
• Infections: Treat viral hepatitis co-infections (HBV, HDV, HIV)

Patients with BMI >25 and albumin <3.5 g/dL are less likely to improve even with successful viral eradication 6.

6. Portal Vein Thrombosis (PVT) Considerations

If PVT develops 9:

• Observation only if: intrahepatic branches involved OR <50% occlusion of main portal/splenic/mesenteric veins
• Anticoagulation indicated if: >50% occlusion OR main portal vein involvement
• Perform endoscopic variceal screening if not already on NSBBs
• In Child-Pugh A patients, direct oral anticoagulants (DOACs), low-molecular-weight heparin, or vitamin K antagonists are all reasonable options

7. Avoid Decompensation Triggers

Key pitfalls to avoid:

• NSAIDs and nephrotoxic drugs (increase risk of renal failure)
• Sedatives and opioids (precipitate encephalopathy)
• Large-volume paracentesis without albumin (in those who develop ascites)
• Infections (maintain low threshold for antibiotic treatment)

8. Dietary Management

• Sodium restriction: 2000 mg/day (88 mmol/day) 4, 5
• Adequate protein intake: Maintain nutrition; protein restriction is NOT recommended
• Fluid restriction: NOT necessary unless severe hyponatremia develops (Na <120-125 mmol/L) 5

Monitoring Strategy

Regular follow-up should include:

• Clinical assessment for signs of decompensation (ascites, encephalopathy, jaundice)
• Laboratory monitoring: CBC, comprehensive metabolic panel, INR, AFP
• Repeat LSM to assess for changes in portal hypertension
• HCC surveillance imaging every 6 months
• Endoscopy if LSM indicates CSPH development

When to Consider Liver Transplantation Evaluation

Refer for transplant evaluation if:

• Development of any decompensation event (ascites, variceal hemorrhage, encephalopathy)
• HCC within Milan criteria
• Progressive liver dysfunction despite treating underlying cause
• MELD score progression

The transition from compensated to decompensated cirrhosis represents a critical turning point, with median survival dropping from 10-12 years to only 1-2 years 8. Therefore, aggressive management of compensated cirrhosis to prevent this first decompensation event is paramount.